NASD · Healthcare · Medical Instruments & Supplies · USA
Pulse Biosciences Inc is a mid cap company (market value between $2 billion and $10 billion) in the Medical Instruments & Supplies industry.
Pulse Biosciences develops medical devices using nanosecond pulsed-field ablation technology to treat various conditions. The company commercializes the nPulse System with disposable applicators for soft tissue ablation in surgical settings and is advancing cardiac products designed to treat atrial fibrillation. Its customers include medical professionals and healthcare institutions.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Pulse Biosciences Inc stock.
Overvalued: intrinsic value $2.50 per share, market price $44.84, margin of safety -1691.7% (as of 2026-11-17).
A 0.8x revenue multiple, discounted for its losses, values the shares at $2.50; the price of $44.84 is 1692% above that value.
17 more funds hold it; the full list is part of the paid plan.
All 52 Medical Instruments & Supplies stocks
22 more in this industry show a wider margin of safety.
PLSE is overvalued (as of the 2026-11-17 close). A 0.8x revenue multiple, discounted for its losses, values the shares at $2.50; the price of $44.84 is 1692% above that value.
$2.50 per share (as of the 2026-11-17 close), against a market price of $44.84. That is a margin of safety of -1691.7%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.